We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+23.93%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$389M
AUM Growth
+$159M
Cap. Flow
+$127M
Cap. Flow %
32.66%
Top 10 Hldgs %
65.31%
Holding
60
New
19
Increased
8
Reduced
9
Closed
22

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$19.1M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$14.6M
3
AKAO
Achaogen Inc
AKAO
+$11M
4
KYNB
Kyntra Bio
KYNB
+$9.16M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$8.63M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$12.9M
2
PFE icon
Pfizer
PFE
+$11.8M
3
KITE
Kite Pharma, Inc.
KITE
+$10.4M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$9.78M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$7.83M

Sector Composition

Rank Sector Weight
1 Healthcare 50.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NERV icon
26
Minerva Neurosciences
NERV
$188M
$4.08M 1.05%
67,112
-4,763
-7% -$273K
KURA icon
27
Kura Oncology
KURA
$922M
$3.87M 0.99%
+258,516
New +$2.43M
RXDX
28
DELISTED
Ignyta, Inc.
RXDX
$3.53M 0.91%
285,728
+35,728
+14% +$368K
MRNS
29
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.52M 0.91%
150,000
+25,000
+20% +$280K
CLVS
30
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$2.88M 0.74%
+35,000
New +$2.77M
INDP icon
31
Indaptus Therapeutics
INDP
$348M
$2.47M 0.64%
+123
New +$1.77M
MDGL icon
32
Madrigal Pharmaceuticals
MDGL
$12.6B
$1.28M 0.33%
+28,536
New +$534K
STDY
33
DELISTED
SteadyMed Ltd
STDY
$867K 0.22%
258,918
-101,708
-28% -$541K
ZSAN
34
DELISTED
Zosano Pharma Corporation
ZSAN
$309K 0.08%
537
-61
-10% -$44.7K
SIOX
35
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$275K 0.07%
+5,000
New +$843K
VTGN icon
36
VistaGen Therapeutics
VTGN
$9.29M
$221K 0.06%
4,604
– –
AVEO
37
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$190K 0.05%
+5,200
New +$161K
CBAY
38
DELISTED
Cymabay Therapeutics
CBAY
$121K 0.03%
+15,000
New +$101K
ABEO icon
39
Abeona Therapeutics
ABEO
$345M
– –
-14,160
Closed -$3.81M
AZN icon
40
CALL
AstraZeneca
AZN
$263B
– –
-245,000
Closed -$16.7M
KMDA icon
41
Kamada
KMDA
$407M
– –
-300,781
Closed -$1.8M
NGNE icon
42
Neurogene
NGNE
$696M
– –
-4,535
Closed -$1.28M
OVID icon
43
Ovid Therapeutics
OVID
$435M
– –
-30,543
Closed -$320K
PFE icon
44
Pfizer
PFE
$140B
– –
-368,932
Closed -$11.8M
VNDA icon
45
Vanda Pharmaceuticals
VNDA
$312M
– –
-462,200
Closed -$7.53M
RNTX
46
Rein Therapeutics
RNTX
$67.7M
– –
-5,705
Closed -$1.27M
TVRD
47
CALL
Tvardi Therapeutics
TVRD
$23.5M
– –
-4,044
Closed -$2.24M
KDNY
48
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-31,000
Closed -$1.77M
OBSV
49
DELISTED
ObsEva SA Ordinary Shares
OBSV
– –
-35,000
Closed -$299K
SRRA
50
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-10,000
Closed -$468K
1
2
3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Nexthera Capital held 60 positions worth $389M, up 69% from $230M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Nexthera Capital deployed $127M of net new capital in Q3 2017, opening 19 new positions and adding to 8 existing holdings. Its largest new stake was Seagen Inc. Common Stock: 373,000 shares worth $20.3M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 71% a quarter earlier.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $7.83M trimmed.

  • Nexthera Capital's largest Q3 2017 buy was Seagen Inc. Common Stock: 373,000 shares worth $20.3M.
  • Nexthera Capital added most to Dova Pharmaceuticals, Inc. Common Stock in Q3 2017, an estimated $5.69M increase.
  • Nexthera Capital's biggest Q3 2017 reduction was Alexion Pharmaceuticals, cutting an estimated $7.83M.
  • Nexthera Capital fully exited Celgene Corp in Q3 2017, selling an estimated $12.9M.
  • Nexthera Capital's ten largest holdings make up 65% of its $389M portfolio in Q3 2017.
  • Nexthera Capital opened 19 new positions and closed 22 in Q3 2017.
  • Nexthera Capital's portfolio value rose 69% quarter-over-quarter to $389M.

Based on Nexthera Capital's 13F filing for Q3 2017, filed 14 Nov 2017.